‘Textbook Conflict Of Interest’: Did Blackstone Pressure FDA To Reverse Course On Moderna mRNA Flu Vaccine?
-
Apr 8, 2026, 3:00 am35 ptsIn 2024, Blackstone, the world’s largest alternative assets manager, launched a $750 million investment in Moderna to support the development of its mRNA flu vaccine. In February, the FDA rejected a review of the vaccine’s Phase 3 clinical trial. By early March, the head of the agency’s…
Welcome to Politomix -- the political news wire where left, right and center mix.
Politomix aggregates the day's political news on the web and your mobile device.







